Abstract: The invention relates to assays for nucleosome remodeling activity using functionalized recombinant mononucleosomes. The functionalized recombinant mononucleosomes comprise a histone octamer comprising recombinant histone H2A, H2B, H3 and H4 proteins and a DNA template comprising a nucleosome positioning sequence that effectively positions the histone octamer and a signal site. The invention further relates to methods of using the assay to quantify enzymatic activity of remodeling enzymes and identifying modulators of remodeling enzyme activity.
Type:
Grant
Filed:
May 18, 2018
Date of Patent:
November 8, 2022
Assignee:
EpiCypher, Inc.
Inventors:
Michael-Christopher Keogh, Martis William Cowles, Matthew Fruge Whelihan
Abstract: Assays and methods for diagnosing and treating autoimmune diseases. Particularly, the invention provides methods for differential diagnosis of specific autoimmune diseases, including autoimmune rheumatic disorders.
Type:
Grant
Filed:
September 17, 2018
Date of Patent:
October 25, 2022
Assignee:
YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventors:
Rachel Sorek, Keren Jakobi-Brook, Pennina Safer, Irun R. Cohen
Abstract: The present invention relates to a method for screening protein-protein interaction inhibitors using a nanopore, a method for analyzing protein structures, a method for analyzing protein-protein interactions, and a kit therefor.
Type:
Grant
Filed:
July 24, 2018
Date of Patent:
October 18, 2022
Assignees:
Korea Research Institute of Bioscience and Biotechnology, Seoul National University R&DB Foundation
Inventors:
Seung Wook Chi, Ki Bum Kim, Dong Kyu Kwak, Mi Kyung Lee, Hong Sik Chae, Ji Hyang Ha
Abstract: The present invention relates to a method for detecting fucosylated alpha1-acid glycoprotein (AGP) in a sample, comprising the steps providing a monovalent fucose-binding peptide having at least 80% identity, such as 85, 90, 95, 99 or 100% identity, to a peptide having an amino acid according to SEQ ID NO: 1, immobilised on a solid phase; bringing the sample into contact with the immobilised fucose-binding peptide; and detecting any fucosylated AGP bound to said fucose-binding peptide. The invention further relates to a method for assessing a risk that a human individual suffers from hepatocellular carcinoma, and to a kit of parts and antibodies useful in the methods according to the invention, and to a peptide useful as an immunizing antigen in production of such antibodies.
Abstract: A universal antibody-mediated biosensor is provided that comprise a biosensor cell line stably expressing a novel chimeric fusion protein that can be used to detect target agents in a sample. The fusion protein has an extracellular antibody-binding domain that binds antibodies without regard to their binding specificity and a signaling domain that induces cellular activation upon antigen binding. Because the fusion protein binds to the Fc region of any antibody, it can serve as a universal pathway between extracellular signaling and intracellular activation. The biosensor can be used to detect the presence of selected antigens in a sample.
Abstract: In some aspects, the present invention provides methods for predicting whether a subject will develop autoantibodies to an anti-TNF? drug during the course of anti-TNF? drug therapy. In other aspects, the present invention provides methods for predicting the level of an anti-TNF? drug in a subject during the course of anti-TNF? drug therapy. Systems for predicting anti-TNF? drug levels and the likelihood of autoantibody formation during the course of anti-TNF? drug therapy are also provided herein. The present invention further provides methods for predicting a clinical outcome (e.g., endoscopic response) of a subject on anti-TNF? drug therapy.
Abstract: This invention provides reagents and methods for diagnosing renal disease. Differential levels of inosine metabolite, and proteins: apolipoprotein C-I, apolipoprotein C-II, fibrinogen alpha chain, or fibrinogen A-alpha chain, kininogen, Inter-Alpha Inhibitor H4 (ITIH4), keratin Type I cytoskeletol 10 cystatin A, cystatin B and other polypeptides and fragments thereof provide biomarkers of renal disease and are described herein.
Type:
Grant
Filed:
September 16, 2019
Date of Patent:
September 6, 2022
Assignee:
IDEXX Laboratories, Inc.
Inventors:
Mahalakshmi Yerramilli, Michael Randolph Atkinson, Murthy V. S. N. Yerramilli
Abstract: Provided are a biomarker for diagnosing of the level of senescence, a composition and kit for diagnosing of the level of senescence to detect the biomarker, and a method of diagnosing the same. According to the composition and kit for the diagnosis of the level of senescence and the method of diagnosing senescence, the level of senescence of a subject is easily diagnosed, the health conditions of the subject are monitored, and a senescence-associated disease is prevented or diagnosed.
Type:
Grant
Filed:
November 30, 2018
Date of Patent:
September 6, 2022
Assignees:
CHA University Industry-Academic Cooperation Foundation, The General Hospital Corporation
Inventors:
Ji Sook Moon, Hak Ho Lee, Ala Jo, Jae Hyun Park, Ji Min Park, Chul Woo Lim, Yu Ri Choi
Abstract: The invention relates to a sensor molecule for detecting a target molecule comprising: (a) a rod-like molecule L and a rod-like molecule R connected to each other by a joint molecule C to form a hinge; (b) a target binding molecule A bonded to the end of rod-like molecule L opposite to the joint molecule C; (c) a binding molecule A? bonded to the end of rod-like molecule R opposite the joint molecule C; wherein the target binding molecule A is arranged to bind to an epitope or nucleic acid sequence of the target molecule to be detected, and binding molecule A? is arranged to bind to the same epitope or same nucleic acid sequence, or portion thereof of the target molecule as target binding molecule A; and wherein the hinge is biased into an open position, such that target binding molecule A and binding molecule A? are biased apart by the hinge. The invention also relates to analyte dependent activation of pharmaceuticals and chemo-toxins.
Type:
Grant
Filed:
September 8, 2017
Date of Patent:
August 30, 2022
Assignee:
University College Dublin, National University of Ireland, Dublin
Abstract: Methods and materials are disclosed for testing biomarkers in a subject suffering from inflammatory bowel disease (IBD) are described herein. Such detection can be useful for diagnosing and treating ulcerative colitis (UC) and Crohn's disease (CD), two forms of IBD that are otherwise difficult to distinguish. The method includes measuring the level of one or more of several biomarkers, including HD5 or MMP-7, which are expressed differentially in patents with UC and CD. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohn's disease.
Abstract: Disclosed herein are compositions, methods, and systems for the purification and/or detection of recombinant and other proteins. In some embodiments, compositions may comprise recombinant protein with one or more sequences having substantial homology to RP-Tag Small or RP-Tag Large. In some cases, the disclosed compositions may be useful in binding or recognizing target proteins.
Abstract: The present invention relates to methods of identifying an epitope on a protein that can be bound by an antibody. Methods of the invention typically involve a step of limited or restricted proteolysis of a protein using a single first protease or a combination of first proteases, and a further proteolysis step using a single second protease or combination of second proteases. The invention also relates to identified epitopes and to antibodies which bind to epitopes that have been identified by methods of the invention.
Type:
Grant
Filed:
October 6, 2017
Date of Patent:
August 9, 2022
Assignee:
OBLIQUE THERAPEUTICS AB
Inventors:
Owe Orwar, Carolina Trkulja, Max Davidson, Jessica Hägglund
Abstract: The present invention relates to a kit and a probe for detecting porous dental hydroxyapatite that includes a protein capable of binding porous dental hydroxyapatite or a detector thereof. The invention also relates to a method for detecting a condition involving porous dental hydroxyapatite that includes detecting in or on a tooth or a sample of the tooth of a subject a protein bound to porous dental hydroxyapatite. The invention also relates to methods for detecting a hypomineralisation developmental dental defect or detecting intact and/or broken MIH enamel, and to a kit and method for removing a protein bound to porous dental hydroxyapatite.
Type:
Grant
Filed:
August 27, 2019
Date of Patent:
August 2, 2022
Assignee:
INCISIVE TECHNOLOGIES PTY LTD
Inventors:
Michael James Hubbard, Jonathan Edward Mangum
Abstract: Bead arrays suitable for analysis by mass spectrometry are disclosed. In an embodiment, a bead array includes multiple reactive sites, each of the reactive sites being capable of binding multiple distinct target analytes.
Abstract: Provided is a method of detecting a biological material, by which quantitative measurement can be performed easily. The method of detecting a biological material in a sample includes: mixing, with the sample, a fusion protein (C) in which a protein (A) capable of binding the biological material and a chemiluminescent protein (B) are fused together and a substrate for the chemiluminescent protein (B); and observing a luminescent signal from the sample, wherein the protein (A) and the protein (B) are linked in such a manner that resonance energy transfer can occur, the protein (A) is either a protein (A1) that can emit fluorescence in a state where the biological material is bound thereto or a protein (A2) capable of binding an autofluorescent molecule as the biological material, and the protein (B) can excite fluorescence or autofluorescence of the protein (A) with its luminescence energy.
Abstract: Methods of using biomarkers in determining the efficacy of a treatment for an organic acidemia in a subject are disclosed herein. Methods of using biomarkers in determining the efficacy of a liver-directed treatment for an organic acidemia in a subject are likewise disclosed herein.
Type:
Grant
Filed:
September 6, 2018
Date of Patent:
June 28, 2022
Assignee:
The United States of America, as represented by the Secretary Department of Health and Human Services
Abstract: Research tool assay for identifying a specific modulator of GNAI, compositions and methods of use. The assay includes combining a drug candidate with GNAI and a C-terminal GIV peptide and determining if the drug candidate inhibits GNAI interaction with the C-terminal GIV peptide; and combining the drug candidate with GNAI and a DAPLE peptide and determining if the drug candidate inhibits GNAI interaction with DAPLE peptide. Also provided are compositions and methods of treatment relating to the same.
Type:
Grant
Filed:
February 22, 2018
Date of Patent:
June 21, 2022
Assignee:
The Regents of the University of California
Abstract: The present invention relates to a method for improving the detection and diagnosis targeting biomarkers using an aqueous two-phase system (ATPS). In one embodiment, the present invention provides a method for improving a diagnostic procedure involving the detection or quantification of one or more biomarkers in liquid biopsy, the method comprises contacting a porous material embedded with ATPS components with a liquid biopsy containing the biomarkers, purifying and concentrating the target biomarkers, and providing a product comprising the target biomarkers for performing the diagnostic procedure.
Abstract: The invention relates to methods of diagnosing, prognosing, or monitoring or staging the progression of non-alcoholic fatty liver disease (NAFLD) using biomarkers. The invention also relates to a method of scoring to determine the severity of NAFLD, and a method of treating NAFLD.
Type:
Grant
Filed:
August 23, 2017
Date of Patent:
June 21, 2022
Assignee:
ShOx Science Limited
Inventors:
Bevin Gangadharan, Abhinav Kumar, Raymond A. Dwek, Nicole Zitzmann, Mark Thursz, Jeremy Francis Lars Cobbold
Abstract: The present invention relates to biomarkers and diagnostic and prognostic methods for vascular diseases. In particular, proteins of platelet-derived exosomes have been identified as biomarkers that can be used to detect platelet activation associated with pathogenesis of vascular diseases, including cardiovascular and cerebrovascular diseases. The invention also provides compositions for detecting biomarkers as well as compositions and methods useful for treating vascular diseases.